Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SL-279252 · 1 trial · 13 indications
Number of participants with treatment emergent adverse events
Number of participants with dose limiting toxicities (DLTs)
| Arm | Type | Description |
|---|---|---|
| SL-279252 | EXPERIMENTAL | Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated |
| Name | Type | Description |
|---|---|---|
| SL-279252 | DRUG | The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L). |
Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply. 1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. 2. Subject has a histologi...
SL-279252 is an investigational small molecule being studied for the treatment of squamous cell carcinoma of the head and neck, as well as other advanced solid tumors and lymphomas. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
SL-279252 is designed to target the PD-1 and OX40L pathways, as indicated by its alternative name PD1-Fc-OX40L. It is being investigated for its potential to modulate immune responses in the treatment of advanced solid tumors and lymphomas.
SL-279252 is being developed by Shattuck Labs, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol STTK. The company is conducting clinical research to evaluate the safety and efficacy of this investigational therapy.
SL-279252 is in Phase 1 clinical development. It is an investigational drug that has not yet received regulatory approval. The Phase 1 trial has been completed, and the drug remains under investigation for the treatment of advanced solid tumors and lymphomas.
SL-279252 has been studied in a Phase 1 clinical trial registered as NCT03894618, titled "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas." The trial enrolled 49 participants and was conducted in the United States, Belgium, Canada, and Spain.
Yes, SL-279252 is also known as PD1-Fc-OX40L. This alternative name reflects its mechanism of action, which involves the PD-1 and OX40L pathways. The drug is being developed by Shattuck Labs, Inc. for the treatment of advanced solid tumors and lymphomas.